Abstract Number: 0648 • ACR Convergence 2021
Improving Post-Rituximab Hypogammaglobulinemia Risk Assessments: A Fellows’ Quality Improvement Initiative
Background/Purpose: Hypogammaglobulinemia following rituximab therapy is a potentially severe complication that can lead to infection-related morbidity and mortality. If recognized, clinicians may prevent infections by…Abstract Number: 1542 • ACR Convergence 2021
Does Adjustment to Dosing and Timing of Immunomodulatory Drugs Impact Immunogenicity of COVID19 Vaccines in Patients with Autoimmune and Inflammatory Rheumatic Disease (AIIRD)?
Background/Purpose: Clinical trials leading to approval of the COVID19 vaccines did not include immunocompromised individuals. Concerns have been raised that immunogenicity of the vaccines may…Abstract Number: 0802 • ACR Convergence 2021
Infection in Rheumatoid Arthritis Patients Treated with Golimumab
Background/Purpose: Biologic use in RA is a well-characterized risk factors for infections. The aim of this analysis was to characterize the incidence of infection in…Abstract Number: 1548 • ACR Convergence 2021
Q Fever as a Mimicker of Rheumatologic Conditions: A Case Series from Two Tertiary Care Academic Centers in Southern California
Background/Purpose: Q fever, an endemic disease in Southern California, is a zoonosis caused by Coxiella burnetii. The infection can present with multiple non-specific acute and chronic manifestations including fever, headache,…Abstract Number: 0010 • ACR Convergence 2021
Relaxed Peripheral Tolerance Drives Broad de Novo Autoreactivity in Severe COVID-19
Background/Purpose: An emerging feature of COVID-19 is the identification of autoreactivity in patients with severe disease that may contribute to disease pathology, however the origins…Abstract Number: 0843 • ACR Convergence 2021
Prevalence and Trends of Infections in Hospitalized Patients with Rheumatoid Arthritis in the United States
Background/Purpose: Rheumatoid arthritis (RA) patients have a higher risk of developing infections as compared to the patients without the diagnosis, and this risk is further…Abstract Number: 1550 • ACR Convergence 2021
Flares and Side Effects After COVID-19 Vaccination in Patients with Rheumatic Diseases
Background/Purpose: There is increasing interest in the safety of COVID-19 vaccination in patients with underlying chronic conditions. We investigated the rates of side effects and/or…Abstract Number: 0088 • ACR Convergence 2021
Evaluation of Patient Characteristics and Clinical Outcomes Among SARS‑CoV‑2‑Diagnosed Patients with and Without RA or PsA Treated with Systemic Therapies: A Retrospective Cohort Study Using US Optum® COVID-19 Electronic Health Record Data
Background/Purpose: Patients with chronic rheumatic diseases are considered to be at increased risk for some infections, with prescribed immunomodulatory (IM) therapies increasing this risk further.…Abstract Number: 0862 • ACR Convergence 2021
Prevalence and Risk Factors for Herpes Zoster Reactivation in 1542 Patients with Rheumatic Diseases
Background/Purpose: To study the prevalence and risk factors of herpes zoster (HZ) infection in patients with rheumatic diseases.Methods: Medical records of patients with rheumatic diseases…Abstract Number: 1554 • ACR Convergence 2021
COVID-19 Vaccine Hesitancy Among Patients with Rheumatic and Other Diseases
Background/Purpose: Vaccination is fundamental to reduce COVID-19 risk and its complications. Vaccine hesitancy is a threat to COVID-19 vaccination uptake. We assessed the frequency of…Abstract Number: 0098 • ACR Convergence 2021
Patients with Chronic Inflammatory Rheumatic Diseases Report a Lower Frequency of Infections Than Controls and They Protect Themselves Well Against SARS-CoV-2 Transmission
Background/Purpose: The SARS-CoV-2 pandemic has affected life in most countries around the world for more than a year now. It is not entirely clear if…Abstract Number: 0937 • ACR Convergence 2021
Evaluation of the Safety of Vedolizumab in Combination with Other Immunosuppression Biological Therapy in Patients with Inflammatory Bowel Disease
Background/Purpose: Inflammatory bowel disease (IBD) causes a wide range of symptomology frequently leading to co-management of disease activity between gastroenterologist and rheumatologists. Recently in efforts…Abstract Number: 1556 • ACR Convergence 2021
Mortality Rate Related to COVID-19 in Rheumatic and Musculoskeletal Diseases (RMDs)
Background/Purpose: In patients with rheumatic and musculoskeletal diseases (RMDs) and infected with Covid – 19, a) we want to assess the mortality rate (MR) related…Abstract Number: 0141 • ACR Convergence 2021
Who Gets Influenza Vaccinations Prior to and After a Diagnosis of RA? Results from the Canadian Early Arthritis Cohort (CATCH)
Background/Purpose: Annual influenza vaccination is recommended for adults with RA, but remains low in established RA. We examined influenza vaccination coverage in the year prior…Abstract Number: 0963 • ACR Convergence 2021
Immunogenicity of COVID-19 Vaccines in Patients with Autoimmune and Inflammatory Rheumatic Diseases (AIIRDs)
Background/Purpose: AIIRD patients may have a blunted immune response to the COVID-19 vaccines, but this is largely uncharacterized as these individuals were not included in…
- « Previous Page
- 1
- …
- 13
- 14
- 15
- 16
- 17
- …
- 32
- Next Page »